Arterial hypertension is revealed in 25–30% of the adult population of the economically developed countries, including Ukraine. In the last 10-15 years there is a high interest to metabolic disorders in arterial hypertension. By estimations of most experts insulin resistance is the leading factor in forming of symptoms of the metabolic syndrome. In development of arterial hypertension in insulin resistance the leading part has the complex influence of hyperinsulinemia and concomitant metabolic disorders. That is why the search of etiological factors and links of pathogenis of arterial hypertension is a highly topical problem since it can be instrumental in determination of new ways of its effective pharmacotherapy. The article presents the own data about the safety of patients with arterial hypertension associated with insulin resistance when using metabolitotropic drugs (rosiglitazone, metformin and thiotriazolin) included in the standard pharmacotherapy (candesartan + perindopril).
Key words: arterialhypertension, insulin resistance, metformin, thiotriazolin
